




Instance: composition-en-62c46661f10ee1d05a1ac34b44b4b3a2
InstanceOf: CompositionUvEpi
Title: "Composition for moventig Package Leaflet"
Description:  "Composition for moventig Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp62c46661f10ee1d05a1ac34b44b4b3a2)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - moventig"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Moventig is and what it is used for  </li>
<li>What you need to know before you take Moventig  </li>
<li>How to take Moventig  </li>
<li>Possible side effects  </li>
<li>How to store Moventig  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What moventig is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What moventig is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Moventig contains the active substance naloxegol. It is a medicine used in adults to treat constipation 
specifically caused by pain medicines, called opioids, (e.g. morphine, oxycodone, fentanyl, tramadol, 
codeine) taken on a regular basis. It is used when laxatives have not provided acceptable relief of 
constipation. </p>
<p>Constipation related to opioids can result in symptoms such as: 
* stomach pain<br />
* rectal straining (having to push very hard to move the stool out of the rectum, which can also 
cause pain in the anus during pushing) 
* hard stools (stools which are hard  like a rock ) 
* incomplete emptying of the rectum (after having a bowel movement, the feeling as if a stool is 
still in the rectum which needs to come out) </p>
<p>In patients taking opioids with constipation, who have tried at least one laxative and had incomplete 
relief of constipation, Moventig has been shown in clinical trials to increase the number of bowel 
movements and improve symptoms of constipation caused by opioids. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take moventig"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take moventig"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Moventig: 
* if you are allergic to naloxegol or similar medicines or any of the other ingredients of this 
medicine (listed in section 6). 
* if your bowels are, or may be, blocked (obstructed) or you have been warned that your bowels 
are at risk of becoming blocked. 
* if you have cancer in your gut or  peritoneum  (the lining of your stomach area), advanced or 
recurrent ovarian cancer or if you are taking medicines used to treat cancer such as  VEGF 
inhibitors  (e.g. bevacizumab). 
* if you are taking certain other medicines such as ketoconazole or itraconazole (to treat fungal 
infections), clarithromycin or telithromycin (antibiotics) or ritonavir, indinavir or saquinavir (to 
treat HIV).  </p>
<p>Do not use Moventig if any of the above applies to you. If you are not sure, talk to your doctor, 
pharmacist or nurse before taking Moventig. </p>
<p>Warnings and precautions 
Talk to your doctor, pharmacist or nurse before taking Moventig: 
* if you have stomach ulcers, Crohn s Disease (an illness where your gut is inflamed), 
diverticulitis (another illness where your gut is inflamed), cancer in your gut or  peritoneum<br />
(the lining of your stomach area), or any conditon that might damage the wall of your bowel<br />
<em> if you currently have unusually severe, persistent or worsening stomach pain<br />
</em> if the natural protective barrier between the blood vessels in the head and in the brain is 
damaged, for example if you have cancer in the brain or the central nervous system, or if you 
have a disease of the central nervous system like multiple sclerosis or Alzheimer s disease <br />
contact your doctor immediately if you experience lack of pain relief from your opioid medicine 
or symptoms of opioid withdrawal syndrome (see section 4).<br />
<em> if you are taking methadone (see section below  Other medicines and Moventig ) 
* if you have had a heart attack within the last 6 months, have heart failure with daily shortness of 
breath or other severe problems with your heart which cause daily symptoms 
* if you have kidney problems   your doctor may tell you to take a different dose (see section 
below  How to take Moventig )<br />
</em> if you have severe liver illness  </p>
<p>If any of the above apply to you, or you are not sure, talk to your doctor, pharmacist or nurse before 
taking Moventig. </p>
<p>Talk to your doctor, pharmacist or nurse whilst taking Moventig: 
* if you develop severe, persistent or worsening stomach pain. This could be a symptom of 
damage to the wall of the gut and can be life-threatening. Tell your doctor immediately, you 
may need a lower dose or to stop taking Moventig.<br />
* if your opioid medicine is to be stopped for more than 24 hours 
* if you experience symptoms of opioid withdrawal syndrome  (see section 4 below). Tell your 
doctor, you may need to stop taking Moventig. </p>
<p>Children and adolescents 
Moventig is not recommended for use in children and adolescents below 18 years of age because it has 
not been studied in these age-groups.  </p>
<p>Other medicines and Moventig 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. Tell your doctor what opioid pain medicines you are taking and the dose of them.   </p>
<p>Do not take Moventig if you are taking any of the following medicines (see section  Do not take 
Moventig ): 
* ketoconazole or itraconazole - to treat fungal infections 
* clarithromycin or telithromycin - antibiotics 
* ritonavir, indinavir or saquinavir   to treat HIV  </p>
<p>Do not take Moventig if any of the above apply to you.  </p>
<p>Tell your doctor, pharmacist or nurse if you are taking any of the following medicines: 
* other medicines for constipation (any laxatives) 
* methadone<br />
* diltiazem or verapamil (for high blood pressure or angina). You may need to take a lower dose 
of Moventig 
* rifampin (an antibiotic), carbmazepine (for epilepsy) or the herbal medicine St. John s wort (for 
depression). You may need to stop taking Moventig 
* medicines called  opioid antagonists  (such as naltrexone and naloxone) which are used to 
counteract the effects of opioids  </p>
<p>If any of the above apply to you, or you are not sure, talk to your doctor, pharmacist or nurse before 
taking Moventig.  </p>
<p>Moventig with drink 
You should not drink large amounts of grapefruit juice whilst taking Moventig. This is because large 
amounts can affect how much of the naloxegol medicine gets into the body.  </p>
<p>Pregnancy and breast-feeding 
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, 
pharmacist or nurse for advice before taking this medicine. As there are additional data from the use of 
this medicine in pregnant women, the use of Moventig during pregnancy is not recommended. </p>
<p>As it is not known whether this medicone is excreted in human milk, do not use Moventig during 
breast-feeding. </p>
<p>Driving and using machines 
Moventig is not expected to affect you being able to drive a car or use any tools or machines.  </p>
<p>Moventig contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per 12.5 mg / 25 mg tablet, that is to say 
essentially  sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take moventig"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take moventig"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is 1 tablet of 25 mg each day.  </p>
<p>Take Moventig in the morning, to avoid bowel movements in the middle of the night. Moventig 
should be taken on an empty stomach at least 30 minutes before the first meal of the day or 2 hours 
after the first meal.  </p>
<p>When treatment with Moventig is started, you do not need to stop using laxatives, unless instructed by 
your doctor. Moventig may be used with or without laxatives. </p>
<p>Discontinue Moventig if treatment with the opioid pain medication is also discontinued. </p>
<p>Your doctor may tell you to take a lower dose of 12.5 mg 
* if you have kidney problems 
* if you take diltiazem or verapamil (for high blood pressure or angina) </p>
<p>Your doctor may tell you to increase the dose to 25 mg depending on how you respond to the 
medicine. </p>
<p>If you have trouble swallowing the tablet 
If you have trouble swallowing the tablet you can crush it and mix with water as follows: 
* Crush the tablet to a powder 
* Pour the powder into half a glass of water (120 ml) 
* Stir and drink immediately 
* To make sure there is no medicine left, rinse the empty glass with another half a glass of water 
(120 ml), and drink it </p>
<p>If you take more Moventig than you should 
If you take more Moventig than you should, talk to a doctor or go to hospital.  </p>
<p>If you forget to take Moventig 
* If you miss a dose of Moventig, take it as soon as you remember. However, if it is less than 
12 hours until your next dose, skip the missed dose. 
* Do not take a double dose to make up for a missed dose. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>Stop taking the medicine and tell your doctor straight away if you develop opioid withdrawal 
symptoms (if you have a combination of three or more of these symptoms: feeling depressed, nausea, 
vomiting, muscle aches, increased tearing, runny nose, dilation of the pupils, goosebumps, excess 
sweating, diarrhoea, yawning, fever or insomnia) which would usually occur within the first few days 
after starting naloxegol. Opioid withdrawal symptoms may affect up to 1 in 100 people. </p>
<p>Other possible side effects: 
Very common (may affect more than 1 in 10 people): 
* stomach pain 
* diarrhoea (passing of frequent, watery stools) </p>
<p>Common (may affect up to 1 in 10 people): 
* passing wind 
* nausea (feeling sick to the stomach) 
* vomiting 
* nasopharyngitis (runny or stuffy nose) 
* headache 
* excessive sweating </p>
<p>Not known (frequency cannot be estimated from the available data):<br />
* allergic reaction 
* gastrointestinal perforation (a hole developing in the bowel wall) </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store moventig"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store moventig"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton after  EXP . The expiry 
date refers to the last day of that month. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Moventig contains<br />
* The active substance is naloxegol. </p>
<p>Each Moventig 12.5 mg film-coated tablet (tablet) contains 12.5 mg naloxegol as 
naloxegol oxalate. </p>
<p>Each Moventig 25 mg film-coated tablet (tablet) contains 25 mg naloxegol as naloxegol 
oxalate. 
* The other ingredients are: </p>
<p>tablet core: mannitol (E421), cellulose microcrystalline (E460), croscarmellose sodium 
(E468)   see section 2 under  Moventig contains sodium , magnesium stearate (E470b), 
propyl gallate (E310) </p>
<p>film-coating: hypromellose (E464), titanium dioxide (E171), macrogol (E1521), iron 
oxide red (E172) and iron oxide black (E172). </p>
<p>What Moventig looks like and contents of the pack 
Moventig 12.5 mg: a mauve coloured, oval, dimensions 10.5 x 5.5 mm film-coated tablet, marked 
 nGL  on one side and  12.5  on the other side. </p>
<p>Moventig 25 mg: a mauve coloured, oval, dimensions 13 x 7 mm, film-coated tablet, marked  nGL<br />
on one side and  25  on the other side. </p>
<p>Moventig 12.5 mg tablets are available in aluminium blisters in pack sizes of 30 or 90 film-coated 
tablets in non-perforated blisters and 30x 1 or 90x1 film-coated tablets in perforated unit dose blisters. </p>
<p>Moventig 25 mg tablets are available in aluminium blisters in pack sizes of 10, 30 or 90 film--coated 
tablets in non-perforated blisters and 10x1, 30x1, 90x1 or 100x1 film-coated tablets in perforated unit 
dose blisters. </p>
<p>Not all pack sizes may be marketed in your country. </p>
<p>Marketing Authorisation Holder </p>
<p>Kyowa Kirin Holdings B.V. 
Bloemlaan 2 
2132NP Hoofddorp 
The Netherlands </p>
<p>Manufacturer </p>
<p>Piramal Pharma Solutions (Dutch) B.V. 
Bargelaan 200 u Leiden 
2333CW 
Netherlands </p>
<p>This leaflet was last revised in </p>
<p>Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu.  </p>         </div>"""      



Instance: composition-da-62c46661f10ee1d05a1ac34b44b4b3a2
InstanceOf: CompositionUvEpi
Title: "Composition for moventig Package Leaflet"
Description:  "Composition for moventig Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp62c46661f10ee1d05a1ac34b44b4b3a2)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - moventig"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Moventig 
3. Sådan skal du tage Moventig 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What moventig is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What moventig is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Moventig indeholder det aktive stof naloxegol. Det er et lægemiddel, der anvendes til voksne til 
behandling af forstoppelse, der er specifikt forårsaget af regelmæssig brug af smertestillende 
lægemidler, der kaldes opioider (f.eks. morfin, oxycodon, fentanyl, tramadol og kodein). Det 
anvendes, når afføringsmidler ikke har givet tilfredsstillende lindring af forstoppelse. </p>
<p>Opioid-relateret forstoppelse kan resultere i symptomer, såsom: </p>
<ul>
<li>
<p>mavesmerter </p>
</li>
<li>
<p>anstrengelse ved afføring (du skal presse meget hårdt for at få afføringen ud af endetarmen, 
hvilket også kan forårsage smerter i endetarmsåbningen, når du presser) </p>
</li>
<li>
<p>hård afføring (afføringer, der er "hårde som sten") </p>
</li>
<li>
<p>ufuldstændig tømning af endetarmen (efter en afføring er der en følelse af, at der stadig er 
afføring i endetarmen, som skal ud) </p>
</li>
</ul>
<p>Det er påvist i kliniske forsøg; at Moventig øger antallet af afføringer og forbedrer opioidforårsagede 
forstoppelsessymptomer hos patienter, der tager opioider, der forårsager forstoppelse, og som har 
prøvet mindst et afføringsmiddel uden at opnå komplet lindring af forstoppelse. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take moventig"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take moventig"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Moventig: </p>
<ul>
<li>
<p>hvis du er allergisk over for naloxegol eller lignende lægemidler eller et af de øvrige 
indholdsstoffer i Moventig (angivet i afsnit 6). </p>
</li>
<li>
<p>hvis dine tarme er, eller der er mistanke om, at de er blokerede, eller hvis du har fået at vide, at 
du har risiko for, at dine tarme bliver blokeret. </p>
</li>
<li>
<p>hvis du har kræft i tarmen eller ’bughinden’ (en hinde i maveregionen) eller fremskreden eller 
tilbagevendende kræft i æggestokkene, eller hvis du tager lægemidler, der anvendes til 
behandling af kræft, såsom "VEGF-hæmmere" (f.eks. bevacizumab). </p>
</li>
<li>
<p>hvis du tager visse andre lægemidler, såsom ketoconazol eller itraconazol (til behandling af 
svampeinfektioner), clarithromycin eller telithromycin (antibiotika) eller ritonavir, indinavir 
eller saquinavir (til behandling af hiv). </p>
</li>
</ul>
<p>Brug ikke Moventig, hvis noget af ovenstående gælder for dig. Hvis du er i tvivl, så spørg lægen, 
apotekspersonalet eller sundhedspersonalet, før du tager Moventig. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sundhedspersonalet, før du tager Moventig: </p>
<ul>
<li>
<p>hvis du har mavesår, Crohns sygdom (en sygdom med betændelse i tarmen), diverticulitis (en 
anden sygdom med betændelse i tarmen), kræft i tarmen eller ’bughinden’ (hinden i 
maveregionen) eller en anden sygdom, som eventuelt kan beskadige tarmvæggen. </p>
</li>
<li>
<p>hvis du for nuværende har usædvanligt stærke, vedvarende eller forværrede mavesmerter. </p>
</li>
<li>
<p>hvis den naturlige beskyttelsesbarriere mellem blodkarrene i hovedet og i hjernen (den såkaldte 
blod-hjerne-barriere) er beskadiget, for eksempel hvis du har kræft i hjernen eller 
centralnervesystemet, eller hvis du har en sygdom i centralnervesystemet, såsom multipel 
sklerose eller Alzheimers sygdom. Kontakt omgående lægen, hvis dine smerter ikke lindres med 
dine opioider, eller hvis du får opioidabstinens (se afsnit 4). </p>
</li>
<li>
<p>hvis du tager methadon (se afsnittet nedenfor "Brug af anden medicin sammen med Moventig"). </p>
</li>
<li>
<p>hvis du har haft et hjertetilfælde inden for de sidste 6 måneder, hvis du har hjertesvigt med 
daglig stakåndethed eller andre alvorlige problemer med hjertet, som forårsager daglige 
symptomer. </p>
</li>
<li>
<p>hvis du har nyreproblemer - Din læge vil eventuelt ordinere en anden dosis (se afsnittet "Sådan 
skal du tage Moventig" nedenfor). </p>
</li>
<li>
<p>hvis du har en alvorlig leversygdom. </p>
</li>
</ul>
<p>Hvis noget af ovennævnte gælder for dig, eller du er i tvivl, så spørg lægen, apotekspersonalet eller 
sundhedspersonalet, før du tager Moventig. </p>
<p>Kontakt lægen, apotekspersonalet eller sundhedspersonalet, mens du tager Moventig: </p>
<ul>
<li>
<p>hvis du får stærke, vedvarende eller forværrede mavesmerter. Det kan være et symptom på 
beskadigelse af tarmvæggen, som kan være livstruende. Kontakt omgående lægen. Du skal 
måske have en lavere dosis eller stoppe med at tage Moventig. </p>
</li>
<li>
<p>hvis din behandling med opioider skal afbrydes i mere end 24 timer. </p>
</li>
<li>
<p>hvis du får symptomer på opioidabstinens (se afsnit 4 nedenfor). Kontakt lægen, det kan være 
nødvendigt at stoppe behandlingen med Moventig. </p>
</li>
</ul>
<p>Børn og unge 
Moventig er ikke anbefalet til brug hos børn og unge under 18 år, fordi det ikke er blevet undersøgt i 
disse aldersgrupper. </p>
<p>Brug af anden medicin sammen med Moventig 
Fortæl lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig. Fortæl 
lægen, hvilke smertestillende opioider, du tager, og i hvilken dosis. </p>
<p>Tag ikke Moventig, hvis du tager et eller flere af følgende lægemidler (se afsnittet "Tag ikke 
Moventig"): </p>
<ul>
<li>
<p>ketoconazol eller itraconazol - til behandling af svampeinfektioner </p>
</li>
<li>
<p>clarithromycin eller telithromycin - antibiotika </p>
</li>
<li>
<p>ritonavir, indinavir eller saquinavir - til behandling af hiv </p>
</li>
</ul>
<p>Tag ikke Moventig, hvis noget af ovenstående gælder for dig. </p>
<p>Fortæl det til lægen, apotekspersonalet eller sundhedspersonalet, hvis du tager et eller flere af følgende 
lægemidler: </p>
<ul>
<li>
<p>andre lægemidler mod forstoppelse (et hvilket som helst afføringsmiddel) </p>
</li>
<li>
<p>methadon </p>
</li>
<li>
<p>diltiazem eller verapamil (mod forhøjet blodtryk eller brystsmerter (angina)). Det kan være, at 
du skal tage en lavere dosis af Moventig. </p>
</li>
<li>
<p>rifampicin (et antibiotikum), carbamazepin (mod epilepsi) eller naturlægemidlet perikon (mod 
depression). Det kan være, at du skal stoppe med at tage Moventig. </p>
</li>
<li>
<p>lægemidler, der kaldes ‘opioidantagonister’ (såsom naltrexon og naloxon), som anvendes til at 
modvirke virkningen af opioider. </p>
</li>
</ul>
<p>Hvis noget af ovennævnte gælder for dig, eller du er i tvivl, så spørg lægen, apotekspersonalet eller 
sundhedspersonalet, før du tager Moventig. </p>
<p>Brug af Moventig sammen med drikke 
Du bør ikke drikke store mængder grapefrugtjuice, når du tager Moventig. Det skyldes, at store 
mængder heraf kan påvirke mængden af medicin (naloxegol), som du får ind i kroppen. </p>
<p>Graviditet og amning 
Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge 
din læge, apotekspersonalet eller sundhedspersonalet til råds, før du tager dette lægemiddel. Da der er 
yderligere data fra anvendelsen af dette lægemiddel til gravide kvinder, frarådes det at bruge Moventig 
under graviditeten. </p>
<p>Da det er ukendt, om dette lægemiddel udskilles i human mælk, må Moventig ikke bruges, hvis du 
ammer. </p>
<p>Trafik- og arbejdssikkerhed 
Moventig forventes ikke at påvirke din evne til at køre bil og betjene værktøj og maskiner. </p>
<p>Moventig indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. 12,5 mg / 25 mg tablet, dvs. det 
er i det væsentlige natrium-frit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take moventig"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take moventig"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller på apoteket. </p>
<p>Den anbefalede dosis er én 25 mg-tablet om dagen. </p>
<p>Tag Moventig om morgenen for at undgå afføring midt om natten. Moventig skal tages på tom mave 
mindst 30 minutter før dagens første måltid eller 2 timer efter dagens første måltid. </p>
<p>Når du begynder på behandlingen med Moventig, behøver du ikke at stoppe med at tage 
afføringsmidler, medmindre din læge beder dig om at stoppe. Moventig kan bruges med eller uden 
afføringsmidler. </p>
<p>Du skal holde op med at tage Moventig, hvis behandlingen med smertestillende opioid bliver stoppet. </p>
<p>Din læge vil eventuelt anvise en lavere dosis på 12,5 mg </p>
<ul>
<li>
<p>hvis du har nyreproblemer. </p>
</li>
<li>
<p>hvis du tager diltiazem eller verapamil (mod forhøjet blodtryk eller brystsmerter (angina)). </p>
</li>
</ul>
<p>Afhængigt af, hvordan du reagerer på medicinen, vil lægen eventuelt øge din dosis til 25 mg. </p>
<p>Hvis du har problemer med at synke tabletten 
Hvis du har problemer med at synke tabletten, kan du knuse den og blande den med vand på denne 
måde: </p>
<ul>
<li>
<p>Knus tabletten til pulver </p>
</li>
<li>
<p>Hæld pulveret i et halvt glas vand (120 ml) </p>
</li>
<li>
<p>Rør rundt og drik straks vandet </p>
</li>
<li>
<p>For at sikre, at der ikke er noget medicin tilbage, skal du skylle det tomme glas med endnu et 
halvt glas vand (120 ml) og drikke det. </p>
</li>
</ul>
<p>Hvis du har taget for meget Moventig 
Kontakt lægen eller tag på skadestuen, hvis du har taget mere af Moventig, end der står i denne 
information, eller mere end lægen har foreskrevet. </p>
<p>Hvis du har glemt at tage Moventig </p>
<ul>
<li>
<p>Hvis du glemmer en dosis af Moventig, skal du tage den, så snart du kommer i tanker om det. 
Hvis der er mindre end 12 timer til din næste dosis, skal du dog springe den glemte dosis over. </p>
</li>
<li>
<p>Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
</li>
</ul>
<p>Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Stop med at tage lægemidlet, og fortæl det straks til lægen, hvis du udvikler opioidabstinens-
symptomer (hvis du har en kombination af tre eller flere af følgende symptomer: nedtrykthed, kvalme, 
opkastning, muskelsmerter, øget tåresekretion, næseflåd, udvidede pupiller, gåsehud, udtalt 
svedtendens, diarré, gaben, feber eller søvnløshed), hvilket normalt vil indtræde i løbet af de første 
dage efter opstart af naloxegol. Opioidabstinens-symptomer kan forekomme hos op til 1 ud af 
100 personer. </p>
<p>Andre bivirkninger: 
Meget almindelige (kan forekomme hos flere end 1 ud af 10 behandlede): </p>
<ul>
<li>
<p>mavesmerter </p>
</li>
<li>
<p>diarré (hyppige, vandige afføring) </p>
</li>
</ul>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 behandlede): </p>
<ul>
<li>
<p>luftafgang fra tarmen </p>
</li>
<li>
<p>kvalme </p>
</li>
<li>
<p>opkastning </p>
</li>
<li>
<p>nasofaryngitis (snue med løbende eller tilstoppet næse) </p>
</li>
<li>
<p>hovedpine </p>
</li>
<li>
<p>udtalt svedtendens </p>
</li>
</ul>
<p>Ikke kendt (hyppigheden kan ikke estimeres ud fra forhåndenværende data): </p>
<ul>
<li>
<p>allergisk reaktion </p>
</li>
<li>
<p>gastrointestinal perforation (der udvikles et hul i tarmvæggen) </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store moventig"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store moventig"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter "EXP". Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Moventig indeholder: </p>
<ul>
<li>Aktivt stof: naloxegol. </li>
<li>Hver Moventig 12,5 mg filmovertrukken tablet (tablet) indeholder 12,5 mg naloxegol 
som naloxegoloxalat. </li>
<li>
<p>Hver Moventig 25 mg filmovertrukken tablet (tablet) indeholder 25 mg naloxegol som 
naloxegoloxalat. </p>
</li>
<li>
<p>Øvrige indholdsstoffer:</p>
</li>
<li>
<p>tabletkerne: mannitol (E421), mikrokrystallinsk cellulose (E460), croscarmellosenatrium 
(E468) - se afsnit 2 under ’Moventig indeholder natrium’, magnesiumstearat (E470b), 
propylgallat (E310). </p>
</li>
<li>filmovertræk: hypromellose (E464), titandioxid (E171), macrogol (E1521), rød jernoxid 
(E172) og sort jernoxid (E172). </li>
</ul>
<p>Udseende og pakningsstørrelser 
Moventig 12,5 mg: en lyserød, oval, filmovertrukken tablet, der måler 10,5 x 5,5 mm og er mærket 
"nGL" på den ene side og "12.5" på den anden side. </p>
<p>Moventig 25 mg: en lyserød oval, filmovertrukken tablet, der måler 13 x 7 mm og er mærket "nGL" 
på den ene side og "25" på den anden side. </p>
<p>Moventig 12,5 mg tabletter fås i aluminiumblistre i pakningsstørrelserne 30 eller 90 filmovertrukne 
tabletter i blistre uden perforering og 30x1 eller 90x1 tabletter i perforerede enkeltdosisblistre. </p>
<p>Moventig 25 mg tabletter fås i aluminiumblistre i pakningsstørrelserne 10, 30 eller 90 filmovertrukne 
tabletter i blistre uden perforering og 10x1, 30x1, 90x1 eller 100x1 tabletter i perforerede 
enkeltdosisblistre. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført i dit land. </p>
<p>Indehaver af markedsføringstilladelsen 
Kyowa Kirin Holdings B.V. 
Bloemlaan 2 
2132NP Hoofddorp 
Holland </p>
<p>Fremstiller 
Piramal Pharma Solutions (Dutch) B.V. 
Bargelaan 200 u Leiden 
2333CW<br />
Holland </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu/. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-62c46661f10ee1d05a1ac34b44b4b3a2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for moventig Package Leaflet for language en"
Description: "ePI document Bundle for moventig Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-62c46661f10ee1d05a1ac34b44b4b3a2"
* entry[0].resource = composition-en-62c46661f10ee1d05a1ac34b44b4b3a2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp62c46661f10ee1d05a1ac34b44b4b3a2"
* entry[=].resource = mp62c46661f10ee1d05a1ac34b44b4b3a2
                            
                    
Instance: bundlepackageleaflet-da-62c46661f10ee1d05a1ac34b44b4b3a2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for moventig Package Leaflet for language da"
Description: "ePI document Bundle for moventig Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-62c46661f10ee1d05a1ac34b44b4b3a2"
* entry[0].resource = composition-da-62c46661f10ee1d05a1ac34b44b4b3a2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp62c46661f10ee1d05a1ac34b44b4b3a2"
* entry[=].resource = mp62c46661f10ee1d05a1ac34b44b4b3a2
                            
                    



Instance: mp62c46661f10ee1d05a1ac34b44b4b3a2
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Moventig 12.5 mg film-coated tablets"
Description: "Moventig 12.5 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/14/962/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Moventig 12.5 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 62c46661f10ee1d05a1ac34b44b4b3a2ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "moventig"

* status = #current
* mode = #working

* title = "List of all ePIs associated with moventig"

* subject = Reference(mp62c46661f10ee1d05a1ac34b44b4b3a2)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#moventig "moventig"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-62c46661f10ee1d05a1ac34b44b4b3a2) // moventig en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-62c46661f10ee1d05a1ac34b44b4b3a2) // moventig da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-62c46661f10ee1d05a1ac34b44b4b3a2
InstanceOf: List

* insert 62c46661f10ee1d05a1ac34b44b4b3a2ListRuleset
    